Provident Financial (PROV) Q3 2025 earnings summary

Executive summary

• Net income for Q3 FY2025 was $1.9 million, up 113% sequentially and 24% year-over-year, driven by higher net interest income and a $391,000 recovery of credit losses, partially offset by increased non-interest expense.

• Net interest margin improved to 3.02%, up 11 bps sequentially and 28 bps year-over-year, reflecting higher yields on interest-earning assets outpacing funding cost increases.

• Loans held for investment increased by $5.4 million quarter-over-quarter to $1.06 billion, mainly from single-family loans.

• Non-performing assets decreased to $1.4 million (0.11% of total assets), down from $2.5 million, with early-stage delinquencies at $199,000.

• Operating expenses rose to $7.9 million, above the expected run rate due to non-recurring litigation and executive search costs.

Financial highlights

• Net interest income for Q3 FY25 rose 8% to $9.2 million; nine-month net interest income was $26.6 million, up slightly year-over-year.

• Diluted EPS for Q3 FY25 was $0.28, up 27% year-over-year and 113% sequentially; nine-month diluted EPS was $0.68, down 12%.

• Allowance for credit losses on loans was $6.6 million (0.62% of gross loans), down from $7.1 million (0.67%) at June 2024.

• Non-interest income increased 7% to $907,000 in Q3 FY25 and to $2.7 million for the nine months.

• Efficiency ratio for Q3 FY25 was 77.64%, up from 76.20% prior year but improved from 81.15% sequentially.

Outlook and guidance

• Management targets moderate asset growth, focusing on expanding single-family, multi-family, and commercial real estate lending.

• Loan origination volume in the next quarter is expected to be similar to the current quarter, in the $18–36 million range.

• Net interest margin is projected to expand further, though at a slower pace.

• Operating expense run rate is expected to be $7.5–$7.6 million per quarter for the remainder of fiscal 2025.

• The company expects to maintain quarterly dividends, subject to board discretion and regulatory considerations.